Oxime/Methoxime is under clinical development by Bodor Laboratories and currently in Phase II for Unspecified Ophthalmological Disorders. According to GlobalData, Phase II drugs for Unspecified Ophthalmological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Oxime/Methoxime LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxime/Methoxime overview
Oxime/Methoxime is under development for the treatment of unspecified ophthalmological disorders.
Bodor Laboratories overview
Bodor Laboratories is a Pharmaceuticals and Healthcare company that Design and manufactures Drug. The company is Headquartered in Miami, Florida, The U.S.
For a complete picture of Oxime/Methoxime’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
